Author

P. Maisonnasse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 4 Organism:non-human primate· 4 Approach:experimental assay· 3 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

R. Marlin· 5 shared R. Le Grand· 4 shared N. Dereuddre-bosquet· 3 shared T. Naninck· 3 shared V. Contreras· 3 shared J. A. Burger· 2 shared J. Lemaitre· 2 shared M. Alexandre· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

R. Marlin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection

D. Lecuyer, R. Nardacci, D. Tannous, E. Gutierrez-Mateyron, A. Deva-Nathan, F. Subra, C. Di Primio, P. Quaranta, V. Petit, C. Richetta, A. Mostefa-Kara, F. Del Nonno, L. Falasca, R. Marlin, P. Maisonnasse, , J.-L. Perfettini

This study identifies P2X7 and NLRP3 inflammasome as host factors required for SARS-CoV-2 infection and shows their role in promoting viral replication.

bioRxiv · Apr 5, 2023Microbiology

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.

A. Marc, R. Marlin, F. Donati, M. Prague, M. Kerioui, C. Herate, M. Alexandre, N. Dereuddre-bosquet, J. Bertrand, V. Contreras, S. Behillil, P. Maisonnasse, S. Van Der Werf, R. Le Grand, J. Guedj

This study examines how SARS-CoV-2 variants of concern affect viral dynamics in non-human primates, finding that most variants escape immune responses, with delta and omicron showing significant differences in viral production rates.

bioRxiv · Nov 9, 2022Microbiology

SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines

M. Alexandre, R. Marlin, M. Prague, C. Severin, N. Kahlaoui, S. Cardinaud, T. Naninck, B. Delache, M. Surenaud, M. Galhaut, N. Dereuddre-Bosquet, M. Cavarelli, P. Maisonnasse, M. Centlivre, C. Lacabaratz, , R. Thiebaut

A mathematical model of viral dynamics is used to identify mechanistic correlates of protection in SARS-CoV-2 vaccines across three non-human primate studies.

bioRxiv · Oct 29, 2021Immunology

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection

G. Sulbaran, P. Maisonnasse, A. Amen, D. Guilligay, N. Bosquet, J. A. Burger, M. Poniman, M. Buisson, S. D. Dylon, T. Naninck, J. Lemaitre, W. Gros, A.-S. Gallouet, R. Marlin, C. Bouillier, , W. Weissenhorn

This study develops a synthetic SARS-CoV-2 S glycoprotein virus-like particle vaccine that protects macaques from infection through strong antibody and T cell responses.

bioRxiv · Jul 26, 2021Immunology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

bioRxiv · Nov 7, 2020Immunology